Handelsbanken Fonder AB raised its position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 71.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 92,300 shares of the company’s stock after acquiring an additional 38,400 shares during the period. Handelsbanken Fonder AB’s holdings in ImmunityBio were worth $236,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Stephens Inc. AR acquired a new stake in ImmunityBio in the fourth quarter valued at about $26,000. Captrust Financial Advisors purchased a new position in shares of ImmunityBio during the 3rd quarter worth approximately $41,000. Virtu Financial LLC acquired a new stake in shares of ImmunityBio in the 3rd quarter valued at approximately $51,000. Mutual Advisors LLC purchased a new stake in shares of ImmunityBio in the fourth quarter valued at approximately $41,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in ImmunityBio by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after acquiring an additional 4,545 shares in the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts have commented on IBRX shares. BTIG Research started coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 target price on the stock. D. Boral Capital reissued a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a report on Friday.
ImmunityBio Stock Performance
Shares of IBRX stock opened at $2.85 on Tuesday. The stock has a market cap of $1.99 billion, a PE ratio of -3.10 and a beta of 0.94. ImmunityBio, Inc. has a 1 year low of $2.28 and a 1 year high of $10.53. The stock has a fifty day moving average price of $3.02 and a 200 day moving average price of $3.73.
ImmunityBio (NASDAQ:IBRX – Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.11. As a group, equities research analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.
ImmunityBio Company Profile
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Recommended Stories
- Five stocks we like better than ImmunityBio
- What is the Nikkei 225 index?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Stock Splits, Do They Really Impact Investors?
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Breakout Stocks: What They Are and How to Identify Them
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX – Free Report).
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
